Why is Sarepta Therapeutics stock sliding today?

Shares of Sarepta Therapeutics dropped 7.6% in pre-market trading after a major Phase III failure in the neuromuscular disease space unnerved investors across the therapeutic category. On September 8, 2026, Novartis announced that its global Phase III HARBOR study, evaluating del-desiran in patients with myotonic dystrophy type 1 (DM1), failed to show a statistically significant improvement over placebo on the primary endpoint of video hand opening time, a novel measure of hand myotonia. The outcome weighed particularly heavily on Sarepta because its SRP-1003 is also an siRNA designed to target DMPK RNA in DM1, although it employs an αvβ6-integrin-targeting ligand rather than the TfR1 mechanism used by del-desiran.

The negative reaction was not confined to Sarepta. A range of pharmaceutical names came under pressure after the Novartis trial setback, with shares of Amgen (AMGN), Eli Lilly (LLY), Ionis Pharmaceuticals (IONS), Dyne Therapeutics (DYN), and Sarepta (SRPT) all sliding in sympathy. The read-through was direct: Dyne’s z-basivarsen is also pursuing DM1 by reducing toxic DMPK RNA, and the market interpreted the HARBOR miss as a potential signal of broader difficulty in achieving clinical success in this indication. The news compounds an already challenging backdrop for Sarepta, which has been navigating tightened 2026 revenue guidance and ongoing regulatory uncertainty surrounding its flagship Duchenne muscular dystrophy franchise.

On the macro front, U.S. futures were mixed this morning, with Dow Jones futures down more than 300 points, while Brent crude approached $100 a barrel following Houthi attacks that halted operations at Saudi energy facilities. The broader market’s risk-off tone, particularly for growth-oriented biotech names, amplified the sector-specific pressure stemming from the Novartis announcement. The HARBOR failure marked Novartis’s second major trial collapse within a matter of days, raising questions about the company’s pipeline and acquisition strategy and further unsettling sentiment across neuromuscular drug developers.

Taken together, the high-profile Phase III failure in a shared disease area, combined with a risk-averse macro environment, produced a compounded negative effect on Sarepta shares in pre-market trading. With SRP-1003 representing a meaningful pipeline asset for the company’s longer-term growth story, investors are reassessing the probability of clinical success in DM1 — pushing the stock to $20.80, well below its 52-week high of $25.32, though still comfortably above its 52-week low of $14.68.

This article was created with the assistance of AI and reviewed by an editor. For more information, please refer to our Terms & Conditions.